{
  "symbol": "SCNX",
  "company_name": "Scienture Holdings Inc",
  "ir_website": "https://scienture.com/investors/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Release - Company News",
          "url": "https://scienture.com/#new-news",
          "content": "[Skip to content](#fl-main-content)\n\n[ ![Scienture Inc](https://scienture.com/wp-content/uploads/2020/03/ezgif-1-4dcc45f80478.png) ](https://scienture.com)\n\nMenu\n\n#  SCIENTURE HOLDINGS, INC.\n\n**SCIENTURE HOLDINGS, Inc** is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the U.S.\n\n  * Enhanced Value: Addressing underserved patients and indications through novel product concepts and innovation\n  * Deep Expertise: R&D, Product Development Research and Manufacturing know-how; Unique product pipeline and focused therapeutic area strategy\n  * Robust Commercial Operations: Complete suite of Sales and Marketing to include Branding, Promotion, Market Access and Distribution\n  * Accomplished leadership and management team: with many years of multidisciplinary experience and deep market knowledge\n  * Disruptive Innovation: Significantly lowers drug and health services costs utilizing our proprietary technology platforms\n  * Strategic Infrastructure: Well-developed, synergistic divisions ready for growth\n\n\n\n##  Our Companies\n\n[ Scienture LLC ](https://scienture.com/scienture-llc/)\n\n[ Integra Pharma Solutions ](https://rxintegra.com/)\n\n##  Leadership Team\n\n### [Executive Team](#)\n\n####  Suren Ajjarapu, Chairman of the Board and Chief Executive Officer\n\nMr. Ajjarapu has served as Chairman of the Board, Chief Executive Officer and Secretary since our acquisition of Trxade Group, Inc., a Nevada corporation (“TRxADE Nevada”) (our predecessor company) on January 8, 2014, and as the Chairman of the Board, Chief Executive Officer and Secretary of TRxADE Nevada since its inception. Mr. Ajjarapu is also Chief Executive Officer of Aesther Healthcare Acquisition Corp., a Special Purpose Acquisition Company traded on Nasdaq under the symbol “AEHA”, as well as a director of Oceantech Acquisition I Corp., traded on Nasdaq under the symbol “OTECU”. Mr. Ajjarapu was a Founder, CEO and Chairman of Sansur Renewable Energy, Inc., a company involved in developing wind power sites in the Midwest, United States, from 2009 to 2012. Mr. Ajjarapu was a Founder, President and Director of Aemetis, Inc., a biofuels company (AMTX.OB) and a Founder, Chairman and Chief Executive Officer of International Biofuels, a subsidiary of Aemetis, Inc., from 2006 to 2009. Mr. Ajjarapu was Co-Founder, COO, and Director Global Information Technology, Inc., an IT outsourcing and systems design company, headquartered in Tampa, Florida with major operations in India from 1995 to 2006. Mr. Ajjarapu holds an MS in Environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in International Finance and Management. Mr. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.\n\n![Suren pic](https://scienture.com/wp-content/uploads/2024/09/Suren-pic.jpg)\n\n![Prashant_Patel pic](https://scienture.com/wp-content/uploads/2024/09/Prashant_Patel-pic.webp)\n\n####  Prashant Patel, Director, President and Chief Operating Officer\n\nMr. Patel has served as our full-time President and COO, and as a director, since our acquisition of TRxADE Nevada on January 8, 2014. Mr. Patel is a registered pharmacist and pharmaceutical consultant with over twenty years of experience in retail pharmacy and pharmaceutical logistics, and the founder of several pharmacies in the Tampa Bay, Florida area. Since October 2008, Mr. Patel has been Managing Member of APAA LLC, a pharmacy and CEO of Pharmaceutical Returns Of America LLC, a pharmaceutical reverse distributor. Mr. Patel graduated from Nottingham University School of Pharmacy and practiced in the UK before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.\n\n####  Shankar Hariharan, Ph.D., Director, CEO-Scienture LLC\n\nDr. Hariharan is the Founder, President and CEO of Scienture, Inc. Dr. Hariharan has over 35 years of experience in successfully leading branded, specialty and generic pharmaceutical businesses and has held several leadership positions at Forest Labs, Par Pharmaceuticals and Amneal Pharmaceuticals.\n\nAt Amneal in his role as the Executive Vice President and Chief Scientific Officer, he oversaw Global Research & Development, Global Regulatory Affairs, and Specialty Product Development and was instrumental in the company achieving significant revenue growth (>$1.5B) with high profit margins.\n\nPrior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in new molecule discovery and product development for key indications in Dermatology, leading to the company’s successful acquisition.\n\nSome notable blockbuster drug products, offering unique value to patients and caregivers, brought to market under Dr. Hariharan’s leadership include Celexa® (>$2B), Lexapro® ($ 4B), Namenda® (>$2B), Megace ES® (>$100M) and over 200 generic products (including many complex generic products). Dr. Hariharan obtained his bachelor’s degree in pharmacy at the Banaras Hindu University (BHU) in India and his Ph.D. in Pharmaceutical Sciences at Northeastern University in Boston, Massachusetts.\n\nDr. Hariharan currently serves on the Board of Depymed, Inc. and on the Advisory Board of New Rhein Healthcare, LLC and MAA Laboratories.\n\n![Shankar Hariharan 1](https://scienture.com/wp-content/uploads/2024/09/Shankar-Hariharan-1.webp)\n\n![Mani site pic](https://scienture.com/wp-content/uploads/2024/09/Mani-site-pic-scaled.webp)\n\n####  Narasimhan Mani, Ph.D., MBA, Director, President-Scienture LLC\n\nDr. Narasimhan Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. He most recently served as the President & CEO for Kesin Pharma Corporation, a Specialty Pharma company with a focus on commercializing specialty and brand products. His past roles include serving as the CEO of Xiromed LLC, a Generics and Specialty drug product company and as the VP, Global Corporate Strategy and BD, at Amneal Pharmaceuticals where he led all the company's strategic initiatives across Global Strategy, Portfolio Management, Business Development and Commercial Operations. His previous experiences also include being the Corporate Finance and Strategic Planning Leader at Johnson & Johnson in New Brunswick, NJ in the pharmaceutical and medical device sectors. He also worked as a Research Scientist and product development leader during his time at Forest Laboratories and Par Pharmaceuticals. He continues to be part of the Executives-in-Residence at New Rhein Healthcare Investors, a life-sciences focused private equity firm and serves as a Board Member at Corsair Pharma, Inc. one of their portfolio companies.\n\nDr. Mani’s journey in the pharmaceutical and healthcare sectors began with his B.Pharm (Hons.). from BITS, Pilani, India which he completed in 1995. His subsequent graduate degrees include M.S. Analytical Chemistry, from the University of Oklahoma, Norman in 1998, Ph.D. in Pharmaceutics, from the University of Georgia, Athens in 2003 and MBA in Finance and Marketing, from Columbia Business School, New York, NY in 2008. Dr. Mani is also the recipient of the 2021 Outstanding 50 Asian Americans in Business Award, in September 2021.\n\n####  Rahul Surana, Ph.D., MBA, EVP & COO-Scienture LLC\n\nResults-driven pharmaceutical executive with a proven track record in pharmaceutical development, strategic leadership, and business development. Over 20 years of brand and generic industry experience working for small, medium and large pharmaceutical companies in various capacities.\n\n![Rahul Aug 2024](https://scienture.com/wp-content/uploads/2024/11/Rahul-Aug-2024-scaled.jpg)\n\n### [Board of Directors](#)\n\n![Suren pic](https://scienture.com/wp-content/uploads/2024/09/Suren-pic.jpg)\n\n####  Suren Ajjarapu,\n\n##### Chairman of the Board\n\nMr. Ajjarapu has served as Chairman of the Board, Chief Executive Officer and Secretary since our acquisition of Trxade Group, Inc. Mr. Ajjarapu holds an MS in Environmental engineering from South Dakota State University and an MBA from the University of South Florida and is also a graduate of the Venture Capital and Private Equity program at Harvard University.\n\n![Prashant_Patel pic](https://scienture.com/wp-content/uploads/2024/09/Prashant_Patel-pic.webp)\n\n####  Prashant Patel\n\nMr. Patel has served as a director, since our acquisition of TRxADE Group Inc. He is a registered pharmacist and pharmaceutical consultant with over twenty years of experience., He graduated from Nottingham University School of Pharmacy and and obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.\n\n![Shankar Hariharan 1](https://scienture.com/wp-content/uploads/2024/09/Shankar-Hariharan-1.webp)\n\n####  ShankarHariharan, Ph.D.\n\nOver 35 years of experience in Pharmaceutical Industry. Involved with development and commercialization of Celexa® (>$2B), Lexapro® ($ 4B), Nemenda® (>$2B), Megace ES® (>$100M). He has founded and has held board positions in several branded and specialty pharmaceutical companies.\n\n![Mani site pic](https://scienture.com/wp-content/uploads/2024/09/Mani-site-pic-scaled.webp)\n\n####  Narasimhan Mani, Ph.D., MBA\n\nExperienced healthcare professional with over 25 years of experience in the pharmaceutical industry. He has held Executive Leadership, P&L responsibilities and Board positions in specialty and brand companies and has led across various product development initiatives and commercial launches (Ritalin®, Morphelan®, Namenda XR® , Nucynta ER ®).\n\n![Donald-Fell](https://scienture.com/wp-content/uploads/2024/09/Donald-Fell.webp)\n\n####  Donald G. Fell\n\nAn economist who formerly headed the Executive and Professional Education Center at the University of South Florida. He earned his undergraduate and graduate degrees in economics from Indiana State University and his ABD in economics from Illinois State University.\n\n![Subbarao](https://scienture.com/wp-content/uploads/2024/09/Subbarao.webp)\n\n####  Subbarao Jayanthi\n\nOver 20 years of strategic consulting and operational experience in the life sciences sector. He has previously held leadership positions at leading management consulting firms. He has undergraduate and graduate degrees in engineering along with an M.B.A. from Kellogg School of Management at Northwestern University.\n\n![Mayur Doshi](https://scienture.com/wp-content/uploads/2024/09/Mayur-Doshi.webp)\n\n####  Mayur Doshi\n\nAn entrepreneur with more than 25 years of experience in the pharmaceutical industry, in the areas of API and finished dosage form distribution. He is an investor in Stem cell research and Immunology and is also involved in SPAC and another public investments.\n\n##  News\n\n####  Sep 2024\n\n[**TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”**](https://finance.yahoo.com/news/trxade-health-inc-announces-name-120100586.html)\n\n####  Sep 2024\n\n[**TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.**](https://finance.yahoo.com/news/trxade-health-inc-announces-name-155900694.html)\n\n[Scroll To Top](#)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "2024 Financial Report",
          "url": "https://scienture.com/financial-reports/",
          "content": "[Skip to content](#fl-main-content)\n\n[ ![Scienture Inc](https://scienture.com/wp-content/uploads/2020/03/ezgif-1-4dcc45f80478.png) ](https://scienture.com)\n\nMenu\n\n## Sorry! That page doesn't seem to exist.\n\n[Scroll To Top](#)\n"
        }
      ]
    }
  ]
}